Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINECRAFT Study of intravenous canrenone in moderate to severe COVID-19 ARDS
2021-001360-20Phase 2Terminated
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of hydroxyprogesterone caproate in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoint: In-hospital death. Started Aug 2021; status: terminated.
02
Drugs
hydroxyprogesterone caproate
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2021-001360-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001360-20.